Boston Scientific - BSX Stock Forecast, Price & News

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Trading Up 1.4 %

Shares of BSX Stock traded up $0.57 during trading hours on Friday, reaching $42.33. The company's stock had a trading volume of 4,019,743 shares, compared to its average volume of 7,749,211. The stock has a market capitalization of $60.51 billion, a P/E ratio of 72.98, a P/E/G ratio of 2.29 and a beta of 0.85. Boston Scientific has a one year low of $34.98 and a one year high of $47.49. The firm's fifty day simple moving average is $38.42 and its 200 day simple moving average is $41.23. The company has a current ratio of 1.31, a quick ratio of 0.86 and a debt-to-equity ratio of 0.51.

Boston Scientific (NYSE:BSX - Get Rating) last issued its quarterly earnings data on Wednesday, July 27th. The medical equipment provider reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.42 by $0.02. The firm had revenue of $3.24 billion for the quarter, compared to analyst estimates of $3.22 billion. Boston Scientific had a return on equity of 14.58% and a net margin of 7.16%. The business's quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the company earned $0.40 EPS. Equities research analysts expect that Boston Scientific will post 1.76 EPS for the current year.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of research reports. Needham & Company LLC raised Boston Scientific from a "hold" rating to a "buy" rating and set a $48.00 price objective on the stock in a report on Friday, May 27th. BTIG Research raised their price objective on Boston Scientific from $45.00 to $50.00 and gave the company a "buy" rating in a report on Thursday, July 28th. Canaccord Genuity Group raised their price objective on Boston Scientific from $43.00 to $45.00 in a report on Thursday, July 28th. StockNews.com cut Boston Scientific from a "buy" rating to a "hold" rating in a report on Thursday, April 21st. Finally, Canaccord Genuity Group decreased their price objective on Boston Scientific from $51.00 to $43.00 and set a "buy" rating on the stock in a report on Wednesday, June 29th. Two equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $46.55.

Insider Activity at Boston Scientific

In related news, EVP Wendy Carruthers sold 7,500 shares of Boston Scientific stock in a transaction that occurred on Friday, June 24th. The stock was sold at an average price of $38.00, for a total transaction of $285,000.00. Following the sale, the executive vice president now directly owns 132,413 shares in the company, valued at $5,031,694. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Wendy Carruthers sold 7,500 shares of Boston Scientific stock in a transaction that occurred on Friday, June 24th. The stock was sold at an average price of $38.00, for a total transaction of $285,000.00. Following the sale, the executive vice president now directly owns 132,413 shares in the company, valued at $5,031,694. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nelda J. Connors sold 16,088 shares of Boston Scientific stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $41.58, for a total value of $668,939.04. Following the sale, the director now owns 4,877 shares in the company, valued at $202,785.66. The disclosure for this sale can be found here. Insiders have sold 59,264 shares of company stock worth $2,382,173 over the last ninety days. 0.71% of the stock is owned by corporate insiders.